Experienced senior Finance Executive with a solid background in management and the broad range of topics that are generally on the CFO/CEO Agenda. Involved in the broader (international) business activities and to interact with a diverse group of people in an international environment, always looking to make progress and improve or optimize people and business. Highly committed to make a sustainable and valuable contribution by taking up a finance executive role in an inspiring and challenging new work environment.
Personal style: strong communicator who combines a helicopter view with an eye for detail, focused on effectively organizing and connecting people and business. High energy, no-nonsense, reliable and hands-on. Team player and team leader.
• Senior Financial Positions, CFO /VP Finance/BoD of companies up to EUR 250 million
• A strong experience in Merger and Acquisitions whereby not only doing the deal is important, also a proven track record in post acquisition activities
• Financial, debt restructuring and private placements
• Financial restructuring and recovery
• Strong strategic planning and implementation and execution of strategic plans
• A proven track record in managing (large) teams, performance / process improvement, turn arounds and change, challenging myself and others to develop and deliver maximum value
• Reporting under different kind of GAAPs (amongst others IFRS and US-GAAP) whereby managing up to 70 different consolidation entities
• Extensive experience in complex financial issues and in other areas such as risk management,
IT, business planning (annual and strategic/long term) and human resources
• Background in amongst others pharmaceutical and pharmaceutical contract manufacturing
• Supply chain management and lean manufacturing management
Meer dan € 145 per uur
24-40 uren per week
Kennis & Vaardigheden
september 2015 tot heden
Taken en verantwoordelijkheden
Als CFO verantwoordelijk voor de opzet en implementatie van een deugdelijke financiele administratie. Daarnaast verantwoordelijk voor M&A activiteiten (overname van twee producten van universiteiten in Europa) en de funding van een BioTech company tot en met fase I van de ontwikkeling.
Op dit moment de financiele strategie uitzetten voor de nabije toekomst (IPO, reverse listing)